MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target
Cardiovascular diseases, involving vasculopathy, cardiac dysfunction, or circulatory disturbance, have become the major cause of death globally and brought heavy social burdens. The complexity and diversity of the pathogenic factors add difficulties to diagnosis and treatment, as well as lead to poo...
Main Authors: | Meng-Wan Zhang, Yun-Jie Shen, Jing Shi, Jian-Guang Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2020.610561/full |
Similar Items
-
miR-223: An Immune Regulator in Infectious Disorders
by: Shun Yuan, et al.
Published: (2021-12-01) -
MiR-223 as a Regulator and Therapeutic Target in Liver Diseases
by: Jiarong Gu, et al.
Published: (2022-03-01) -
Relevance of miR-223 as Potential Diagnostic and Prognostic Markers in Cancer
by: Faisal Aziz, et al.
Published: (2022-02-01) -
Hsa-miR-223-3p participates in the process of anthracycline-induced cardiomyocyte damage by regulating NFIA gene
by: Han Xiao, et al.
Published: (2023-07-01) -
miR-223: A Key Regulator in the Innate Immune Response in Asthma and COPD
by: Mirjam P. Roffel, et al.
Published: (2020-05-01)